Second quarter results exceeded guidance, with revenue up 8.7% and adjusted EPS up 12.1% year-over-year. Both clinical and commercial segments showed strong growth, driven by AI-enabled solutions and robust demand. Full-year guidance was raised across all key metrics.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.